SCHEMBL14634149

SCHEMBL14634149

CNc1nc(Nc2cc(C)cc(N3CCCC3)c2)ncc1-c1n[nH]c2c(F)cccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 12/20 0.43
CDK2 P24941 12/20 0.43
CDK9 P50750 12/20 0.43
CCNA2 P20248 11/20 0.43
CDK1 P06493 8/20 0.40
CCNB1 P14635 8/20 0.40
CDK7 P50613 7/20 0.40
CCNH P51946 7/20 0.40
CCNA1 P78396 5/20 0.40
CCNE1 P24864 1/20 0.39
AURKA O14965 1/20 0.38
JAK1 P23458 2/20 0.37
JAK2 O60674 1/20 0.37
FLT3 P36888 1/20 0.37
RIPK2 O43353 1/20 0.36
EGFR P00533 1/20 0.36
BTK Q06187 1/20 0.36
JAK3 P52333 1/20 0.36
PRKCQ Q04759 1/20 0.36
CHEK1 O14757 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634231 0.93 CCNT1 (0.48) CCNT1CDK2CDK9CCNA2CDK1
SCHEMBL2468022 0.89 JAK2 (0.49) CCNT1CDK2CDK9CCNA2CDK1
SCHEMBL14634077 0.82 JAK1 (0.40) CCNT1CDK2CDK9CCNA2CDK1
SCHEMBL14633512 0.78 ADORA3 (0.48) CDK2CDK9CDK1CDK7AURKA
SCHEMBL14633979 0.77 CHEK1 (0.34) CCNT1CDK2CDK9CCNA2CDK1
SCHEMBL14634156 0.75 EPHB4 (0.49)
SCHEMBL14634260 0.75 JAK2 (0.45) CCNT1CDK2CDK9CCNA2CDK1
SCHEMBL14634234 0.75 JAK3 (0.42) CCNT1CDK2CDK9CCNA2CDK1
SCHEMBL14633989 0.74 SYK (0.42) CCNT1CDK2CDK9CCNE1AURKA
SCHEMBL14633643 0.72 CDK2 (0.39) CCNT1CDK2CDK9CCNA2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 CCNT1 331/4885CDK2 22/4885CDK9 55/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 CCNT1 282/4885CDK2 1/4885CDK9 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.